

ENGIMMUNE THERAPEUTICS RAISES CHF 15.5M IN SEED FINANCING ROUND

Posted on 6 May 2022



Category: [Banking & Finance](#)

Tags: [Alexander Gutmans](#), [dx1](#), [Karina Tschon](#), [Lena Götzinger](#), [Lucas Maurer](#), [Michelle Bruni](#), [Walder Wyss](#)



Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch.

Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment.

Proceeds from the financing will be used to develop novel T-cell receptor therapeutics and further build Engimmune Therapeutics' pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.

[Walder Wyss](#) advises Engimmune Therapeutics in connection with the financing round. The team includes **Alexander Gutmans** (partner, corporate/m&a and venture capital, pictured), **Karina Tschon** (associate, corporate/m&a and venture capital), **Lena Götzinger** (associate IP/licensing), **Lucas Maurer** (associate, corporate/m&a and venture capital) and **Michelle Bruni** (senior associate, corporate/m&a and tax).